Prevalence of Micro- and Macrovascular Diabetes Complications at Time of Type 2 Diabetes Diagnosis and Associated Clinical Characteristics: A Cross-sectional Baseline Study of 6958 Patients in the Danish DD2 Cohort
Overview
Authors
Affiliations
Aims: To examine the prevalence of micro- and macrovascular complications and their associated clinical characteristics at time of type 2 diabetes (T2D) diagnosis.
Methods: We examined the prevalence of complications and associated clinical characteristics among 6958 newly diagnosed T2D patients enrolled in the prospective Danish Center for Strategic Research in T2D cohort during 2010-2016. We calculated age- and gender-adjusted prevalence ratios (aPRs) of complications using log-binomial and Poisson regression.
Results: In total, 35% (n=2456) T2D patients had diabetic complications around diagnosis; 12% (n=828) had microvascular complications, 17% (n=1186) macrovascular complications, and 6% (n=442) had both. HbA1c levels of ≥7% were associated with microvascular complications [HbA1c 7%-8%; aPR: 1.35, 95% confidence interval (CI): 1.12-1.62] but not macrovascular complications [aPR: 0.91, 95% CI: 0.76-1.08]. High C-peptide≥800pmol/L was associated with macrovascular [aPR 1.34, 95% CI: 1.00-1.80] but not microvascular [aPR 0.97, 95% CI: 0.71-1.33] complications. Macrovascular complications were associated with male sex, age>50years, obesity, hypertriglyceridemia, low HDL cholesterol, smoking, elevated CRP levels, and anti-hypertensive therapy. Microvascular complications were associated with high blood pressure, hypertriglyceridemia, and absence of lipid-lowering therapy.
Conclusions: One-third of patients with T2D had diabetes complications around time of diagnosis. Our findings suggest different pathophysiological mechanisms behind micro- and macrovascular complications.
Aldakhil R, Greenfield G, Lammila-Escalera E, Laranjo L, Hayhoe B, Majeed A J Diabetes Sci Technol. 2025; :19322968251316585.
PMID: 39960237 PMC: 11833803. DOI: 10.1177/19322968251316585.
Hsu P, Liao P, Huang S, Chang H, Chiang J, Lo L Ann Med. 2025; 57(1):2458766.
PMID: 39898556 PMC: 11792153. DOI: 10.1080/07853890.2025.2458766.
Insights into the molecular underpinning of type 2 diabetes complications.
Singh A, Bocher O, Zeggini E Hum Mol Genet. 2025; 34(6):469-480.
PMID: 39807636 PMC: 11891870. DOI: 10.1093/hmg/ddae203.
Aldakhil R, Lammila-Escalera E, Hayhoe B, Majeed A, Greenfield G, Neves A BMJ Open. 2024; 14(11):e082452.
PMID: 39488411 PMC: 11535670. DOI: 10.1136/bmjopen-2023-082452.
Lee E Diabetes Metab J. 2024; 48(5):1005-1007.
PMID: 39313233 PMC: 11449823. DOI: 10.4093/dmj.2024.0417.